What question did this study set out to answer?

This research aims to evaluate the agreement between laboratory and point-of-care creatinine assessments for identifying risk of post-contrast acute kidney injury.

March 28, 2026Open Access

Wcn26-6607 Agreement Between Laboratory and Point-of-Care Creatinine–based Risk Assessment for Post-Contrast Acute Kidney Injury in Patients Undergoing Angiography

Key Result

Early adjunctive tolvaptan therapy in acute decompensated heart failure improved symptom relief and diuresis while reducing worsening renal function, oxygen support duration, and hospital stay.

Key Points

This research aims to evaluate the agreement between laboratory and point-of-care creatinine assessments for identifying risk of post-contrast acute kidney injury.
Conducted an observational analysis comparing laboratory and point-of-care creatinine results.
Included patients undergoing angiography to assess risk for acute kidney injury after contrast use.
Evaluated the effectiveness of tolvaptan as adjunctive therapy for acute decompensated heart failure (ADHF).
Early use of tolvaptan improved symptom relief and increased urination rates.
Tolvaptan reduced worsening renal function and length of hospital stay.
Patients without chronic kidney disease experienced greater renal protective benefits.

Structured PICO

Does point-of-care creatinine testing agree with laboratory measurements for risk assessment of post-contrast acute kidney injury in patients undergoing angiography?

Population

Patients undergoing contrast-enhanced angiography for acute stroke or myocardial infarction

Intervention

Point-of-care (POC) creatinine testing

Comparator

Standard laboratory creatinine measurements

Outcome

Agreement between laboratory- and POC-based risk categories for post-procedural acute kidney injury (AKI)surrogate

Point-of-care creatinine testing provides almost perfect diagnostic agreement with standard laboratory measurements for stratifying post-contrast AKI risk in acute angiography settings.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Conclusion:Early adjunctive therapy with tolvaptan in ADHF significantly improved early symptom relief and diuresis, while reducing the incidence of worsening renal function, duration of oxygen support, and length of hospital stay.Subgroup analysis suggests that patients without underlying CKD derive greater renal protective benefit from tolvaptan.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.

Bookmark

View Full Paper